Xenobiotic Biotransformation
Xenobiotic Biotransformation - Related Videos
01:16
Drug Biotransformation: Overview
0 Views •
2023
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
01:28
Drug Biotransformation: Overview
0 Views •
2025
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
08:08
Determination of the Transport Rate of Xenobiotics and Nanomaterials Across the Placenta using the ex vivo Human Placental Perfusion Model
0 Views •
Cited by 56 •
2013
The ex vivo dual recirculating human placental perfusion model can be used to investigate the transfer of xenobiotics and nanoparticles across the human placenta. In this video protocol we describe the equipment and techniques required for a successful execution of a placenta perfusion.
01:19
Factors Affecting Drug Biotransformation: Biological
0 Views •
2025
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity. Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects. Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
01:21
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
0 Views •
2025
A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism. The drug's acidity or basicity is essential in determining the metabolic...
FAQs
Phase I and phase II reactions can change a compound’s properties in different ways. Oxidation, reduction, or hydrolysis may modify the original chemical, while conjugation attaches polar groups that generally support further handling and removal. Considering both stages helps explain why a substance may become more water-soluble, easier to eliminate, or transformed into a metabolite with different biological effects.
Not every metabolic change is protective. Xenobiotic biotransformation can reduce a compound’s activity and promote elimination, but it can also generate active or toxic metabolites. In clinical interpretation, the parent substance alone therefore may not predict the full response. This distinction is relevant when evaluating therapeutic efficacy, adverse effects, and the consequences of altered metabolic pathways.
Transport and excretion determine whether products of biotransformation actually leave the body. Increasing water solubility can make removal more feasible, but processing is not complete until the resulting substances are transported and excreted. This connected sequence matters clinically because changes along it can influence how long compounds or metabolites persist and affect exposure.
Clinicians can use knowledge of biotransformation to consider whether one substance may alter the handling of another. Because metabolic pathways affect drug efficacy, adverse effects, and metabolite formation, pathway changes can produce clinically meaningful interactions. This framework supports assessment of treatment response and helps inform dosing decisions when the expected exposure or effect may change.
People may differ in how their biotransformation pathways modify and remove foreign chemicals. That variability can contribute to differences in drug efficacy, adverse effects, and the dosing needed for an appropriate response. Clinical consideration of these differences is important because the same administered compound may not produce identical outcomes across individuals.
It becomes especially relevant when clinicians must balance therapeutic benefit against unwanted effects or account for possible metabolic interactions. Examining phase I modification, phase II conjugation, metabolite activity or toxicity, and subsequent removal provides a mechanistic context for interpreting treatment outcomes. This information can support predictions about efficacy, adverse effects, and appropriate dosing.